625114-41-2

Upstream product

• 588940-69-6 (3-chloro-4-methylsulfanyl-phenyl)-N-[2(R)-hydroxy-1(R)-methyl-2(R)-phenyl-ethyl]-N-methyl acetamide 
• 87776-75-8 (3-chloro-4-methylsulfanyl-phenyl)-acetic acid 
• 625827-26-1 (2R,3R)-2,3-diphenyl-1,4-dioxaspiro[4.4]non-6-ene 
• 393165-02-1 (3-chloro-4-methylsulfanyl-phenyl)-oxo-acetic acid methyl ester 
• 930-30-3 cyclopent-2-enone 
• 5049-61-6 2-Aminopyrazine 
• 625114-43-4 (2R)-2-(3-chloro-4-methanesulfonylphenyl)-3-[(1R)-3-oxocyclopentyl]propanoic acid 
• 17733-22-1 2-chlorothioanisole 
• 1003013-93-1 (R)-2-(3-chloro-4-methanesulfonyl-phenyl)-3-((R)-3-oxo-cyclopentyl)-propionyl chloride 

Downstream Products

• 952517-38-3 iso-propanol solvate of 2(R)-(3-chloro-4-methanesulfonyl-phenyl)-3-((R)-3-oxo-cyclopentyl)-N-pyrazin-2-yl-propionamide 

Relevant academic research and scientific papers

Discovery of piragliatin-first glucokinase activator studied in type 2 diabetic patients

Glucokinase (GK) activation as a potential strategy to treat type 2 diabetes (T2D) is well recognized. Compound 1, a glucokinase activator (GKA) lead that we have previously disclosed, caused reversible hepatic lipidosis in repeat-dose toxicology studies.

CRYSTALLINE ISOPROPANOL SOLVATE OF GLUCOKINASE ACTIVATOR

Provided is a crystalline IPA solvate of 2(R)-(3-chloro-4-methanesulfonyl-phenyl)- 3-((R)-3-oxo-cyclopentyl)-N-pyrazin-2-yl-propionamide as a glucokinase activator which increases insulin secretion in the treatment of, for example, type II diabetes.

Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators

2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a polar ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.